Progenics Pharmaceuticals develops medicines and other technologies to target and treat cancer in the United States and internationally. The Company’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma.